Abstract P6-10-04: Outcome of Triple Negative Breast Cancer in Patients with or without Deleterious BRCA Mutations
| Autor: | Gn. Hortobagyi, Jennifer K. Litton, Constance Albarracin, Ugur Akar, Angelica M. Gutierrez-Barrera, A. M. Gonzalez-Angulo, Banu Arun |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty animal structures endocrine system diseases business.industry Genetic counseling BRCA mutation Cancer medicine.disease female genital diseases and pregnancy complications Breast cancer Internal medicine medicine In patient Stage (cooking) skin and connective tissue diseases business Survival analysis Triple-negative breast cancer |
| Zdroj: | Cancer Research. 70:P6-10 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Background: Triple-negative breast cancer (TNBC) affects 10-17% of all breast cancers and is associated with a poor prognosis. The biology of TNBC is poorly understood; however, it has been shown that up to 60% of BRCA1 mutation carriers develop TNBC. The aim of this study was to determine if there were differences in the progression-free survival (PFS) and overall survival (OS) rates of BRCA mutation-associated TNBC and Non-BRCA mutation-associated TNBC. Methods: Patients with TNBC who were referred between 1997 and 2010 for genetic counseling were included in the analysis. Data was collected from a prospectively maintained IRB-approved research database. All patients with one primary breast cancer and negative expression of ER, PR, and Her2 were included in this study. A Kaplan-Meier survival analysis was performed to determine survival outcomes. Results: Out of 98 TNBC patients, 48 (48 %) were BRCA negative, and 47 (49%) were found to have a deleterious BRCA mutation (42 BRCA1 and 5 BRCA 2); 3 (3%) patients had a variant of uncertain significance in BRCA2 and were removed from study. The median age of diagnosis for BRCA positive TNBC was 42 years (range, 21-71) and for BRCA negative TNBC was 40.5 years (range, 21-64). There were no significant differences between age at diagnosis, nuclear grade, stage (I-III), or tumor histology of BRCA positive and BRCA negative TNBCs. The PFS for BRCA positive patients was 230.7 (range, 2-271) months and for BRCA negative was 203.1 (range, 2-258) months (p = 0.19). The overall survival (OS) for BRCA positive patients was 263.4 (range, 2-292) months and for BRCA negative 236.2 (2-279) months (p = 0.39). Conclusion: Outcome of triple-negative breast cancer is not different in BRCA mutation carriers versus non carriers. Further studies need to evaluate whether different therapies will change the outcome in these subgroups of TNBC. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-10-04. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|